DE60323333D1 - Fab-fragmente humaner monoklonaler antikörper mit protein - Google Patents

Fab-fragmente humaner monoklonaler antikörper mit protein

Info

Publication number
DE60323333D1
DE60323333D1 DE60323333T DE60323333T DE60323333D1 DE 60323333 D1 DE60323333 D1 DE 60323333D1 DE 60323333 T DE60323333 T DE 60323333T DE 60323333 T DE60323333 T DE 60323333T DE 60323333 D1 DE60323333 D1 DE 60323333D1
Authority
DE
Germany
Prior art keywords
protein
monoclonal antibody
human monoclonal
fab fragments
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60323333T
Other languages
German (de)
English (en)
Inventor
Roberto Burioni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Antibodies And Biotechnologies Srl Sm
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60323333D1 publication Critical patent/DE60323333D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60323333T 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit protein Expired - Lifetime DE60323333D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
PCT/IT2003/000032 WO2003064473A2 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity

Publications (1)

Publication Number Publication Date
DE60323333D1 true DE60323333D1 (de) 2008-10-16

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323333T Expired - Lifetime DE60323333D1 (de) 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit protein

Country Status (17)

Country Link
US (2) US20050084845A1 (enExample)
EP (1) EP1476468B9 (enExample)
JP (1) JP4287280B2 (enExample)
KR (1) KR101002791B1 (enExample)
CN (1) CN1856508A (enExample)
AT (1) ATE407147T1 (enExample)
AU (1) AU2003208000B2 (enExample)
CA (1) CA2474801C (enExample)
DE (1) DE60323333D1 (enExample)
DK (1) DK1476468T3 (enExample)
EA (1) EA009861B1 (enExample)
ES (1) ES2314179T3 (enExample)
IT (1) ITRM20020049A1 (enExample)
NZ (1) NZ534922A (enExample)
RU (1) RU2004126238A (enExample)
WO (1) WO2003064473A2 (enExample)
ZA (1) ZA200406187B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
JP2010519916A (ja) * 2007-03-06 2010-06-10 リボバックス バイオテクノロジーズ ソシエテ アノニム 風疹ウイルスに特異的な抗体
CN101809033A (zh) 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
PE20091109A1 (es) * 2007-12-17 2009-08-12 Medical Res Council Technology Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ITTO20080964A1 (it) * 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
EP2542892A4 (en) 2010-03-01 2013-11-27 Vincent Agnello PROGNOSTIC MARKER FOR CRYOGLOBULINEMIC VASCULARITY AND B-CELL MALIGNANCIES IN HCV INFECTED PATIENTS
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
AU2020413304B2 (en) 2019-12-27 2025-07-17 Chiome Bioscience Inc. Anti-CDCP1 antibody
US20230312744A1 (en) 2020-09-02 2023-10-05 The University Of Tokyo Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same
EP4566627A1 (en) 2022-07-28 2025-06-11 The University of Tokyo Neurotrimin function inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951646B1 (en) * 1998-07-21 2005-10-04 Genmab A/S Anti hepatitis C virus antibody and uses thereof
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
WO2002005560A2 (en) 2000-07-12 2002-01-17 General Instrument Corporation Method and apparatus for downloading objects via an inband channel with minimal subscriber impact
EP1355947A2 (en) * 2000-12-01 2003-10-29 The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c

Also Published As

Publication number Publication date
ITRM20020049A1 (it) 2003-07-30
WO2003064473A2 (en) 2003-08-07
NZ534922A (en) 2008-07-31
CA2474801A1 (en) 2003-08-07
US20080241162A1 (en) 2008-10-02
AU2003208000B2 (en) 2010-05-20
KR101002791B1 (ko) 2010-12-21
EA009861B1 (ru) 2008-04-28
KR20040077745A (ko) 2004-09-06
CN1856508A (zh) 2006-11-01
WO2003064473A3 (en) 2003-12-24
EP1476468B9 (en) 2009-04-08
DK1476468T3 (da) 2009-01-19
ZA200406187B (en) 2006-06-28
CA2474801C (en) 2012-03-20
US20050084845A1 (en) 2005-04-21
EP1476468A2 (en) 2004-11-17
JP2005531286A (ja) 2005-10-20
EP1476468B1 (en) 2008-09-03
US7727529B2 (en) 2010-06-01
EA200401081A1 (ru) 2005-10-27
RU2004126238A (ru) 2005-04-20
JP4287280B2 (ja) 2009-07-01
ATE407147T1 (de) 2008-09-15
ITRM20020049A0 (it) 2002-01-30
ES2314179T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
DE60323333D1 (de) Fab-fragmente humaner monoklonaler antikörper mit protein
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
NZ527283A (en) Modified antibodies and methods of use
CR8108A (es) Tratamiento con anticuerpos anti-vegf
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2004018519A3 (en) Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
EP1748075A4 (en) RECOMBINANT CHEMOKIN ANTIGEN VACCINE
WO2001072334A3 (en) Methods for treating disease with antibodies to cxcr3
WO2023159061A3 (en) Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein
TW200635953A (en) Specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENERAL ANTIBODIES AND BIOTECHNOLOGIES S.R.L.,, SM